standard care
[용어속성] Term
Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis
COVID-19 입원 환자에서 약물의 임상 효과: 체계적인 검토 및 메타 분석
Meta-Analysis
[키워드] Analysis
antivirals
article
benefit
Chloroquine
clinical
clinical effectiveness
Clinical improvement
conducted
convalescent plasma
country
COVID-19
COVID-19 infection
COVID-19 pandemic
data extraction
databases
Dexamethasone
diagnosis of SARS-CoV-2
drug
drugs
duration of hospitalization
Effectiveness
hospitalized patient
hospitalized patients
Hydroxychloroquine
Infection
Lopinavir
Meta-analysis
Mortality
outcome
oxygen
oxygen support
patients treated
randomized clinical trial
randomized clinical trials
reduce mortality
reduction
Remdesivir
resources
retrieved
risk
Ritonavir
SARS-CoV-2
SARS-COV-2 infection
severe adverse events
standard care
systematic review
Treatment
Ventilation
virological clearance
with COVID-19
[DOI] 10.1177/17534666211007214 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1177/17534666211007214 PMC 바로가기 [Article Type] Meta-Analysis
Pediatric subspecialty telemedicine use from the patient and provider perspective
Clinical Research Article
[키워드] Analysis
Care
Clinical use
COVID-19
COVID-19 pandemic
hospital
Impact
Observational data
orthopedic
pandemic
Patient
pediatric
Pediatric patient
performed
Perspective
reported
Result
rheumatology
Satisfaction
standard care
suggested
Telemedicine
telemedicine visit
the mean
the patient
[DOI] 10.1038/s41390-021-01443-4 PMC 바로가기 [Article Type] Clinical Research Article
[DOI] 10.1038/s41390-021-01443-4 PMC 바로가기 [Article Type] Clinical Research Article
Interleukin-6 blocking agents for treating COVID-19: a living systematic review
COVID-19 치료를 위한 인터루킨-6 차단제: 살아있는 체계적인 검토
Meta-Analysis
[키워드] 95% CI
adverse event
adverse events
age
all-cause mortality
anti-IL6
approach
articles
available data
average
baseline
benefit
Bia
blocking agent
blocking agents
Brazil
can not
Care
certainty
certainty of evidence
China
clinical
Clinical improvement
Cochrane COVID-19 Study Register
collected data
conducted
coronavirus disease
Coronavirus disease 2019
COVID-19
Critical
Critical disease
Data collection
death
defined
disease
disease severity
Efficacy and safety
eight
evaluate
evaluated
Evidence
excluded
FIVE
Follow-up
France
Health Organization
heterogeneity
hospital discharge
identify
IL-6
IL-6 blocking
Immune system dysfunction
immunosuppressive
incidence
Inclusion
individual
individual patient data meta-analyses
Inflammation
interleukin
interleukin 6
interleukin 6 (IL-6
Intubated
intubated patient
intubated patients
Italy
male
mechanical ventilation
Meta-analysis
methodology
Mild
moderate
Mortality
multicentre
nine
no increase
not intubated
organ support
Other outcomes
outcome
outcomes
oxygen
participant
Participants
Patient
patient data
patients with COVID-19
peer-reviewed
people with COVID-19
Placebo
platform
Platform trial
progression
proportion
protocol
randomised
randomised controlled trial
Randomised controlled trials
ranged
RCT
RCTs
reduce
Registered
registry
reported
risk of bia
Safety
sarilumab
score
searched
Selection
Serious Adverse Event
Serious Adverse Events
Seven
severe coronavirus disease
severity
siltuximab
standard care
Standard of care
subgroups of patient
systematic review
Tocilizumab
Tolerance
Treatment
Trial
trial participant
trial participants
trials
unlikely
USA
WHO
World Health Organization
[DOI] 10.1002/14651858.CD013881 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1002/14651858.CD013881 PMC 바로가기 [Article Type] Meta-Analysis
Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review
COVID-19 치료를 위한 현재 연구 약물의 효능: 범위 검토
Review Article
[키워드] anticoagulant therapies
anticoagulant therapy
Arbidol
available data
clinical recovery
ClinicalTrials
Cochrane Library
conducted
coronavirus
Corticosteroids
COVID-19
COVID-19 patients
COVID-19 virus
database
databases
drug
drugs
effective
Efficacy
eligibility criteria
eligible
Evidence
Favipiravir
Final
ICTRP
Immunoglobulin
individuals
initial
interferon
interferons
Lopinavir
Lopinavir-ritonavir
mesenchymal stem cell
no significant difference
Plasma transfusion
Pneumonia
Prognosis
promote
Recovery time
Ritonavir
Sample size
SARS-CoV-2
standard care
stem cell
Stem cell transplantation
systematic literature search
Tocilizumab
Treatment
treatment for COVID-19
treatment results
treatments for COVID-19
treatments of COVID-19
Viral
viral clearance
virus
[DOI] 10.1080/07853890.2021.1875500 PMC 바로가기 [Article Type] Review Article
[DOI] 10.1080/07853890.2021.1875500 PMC 바로가기 [Article Type] Review Article
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
COVID-19 치료를 위한 중재: 메타 분석 및 시험 순차 분석이 포함된 살아있는 체계적인 검토의 두 번째 판(The LIVING 프로젝트)
Meta-Analysis
[키워드] 95% CI
95% confidence interval
adjusted
Admission
aggregate data meta-analyses
all age group
all age groups
all-cause mortality
Analysis
boundary
bromhexine
caused
certainty
certainty of evidence
Clinical research
Clinical significance
Cochrane guidelines
comparison
Comparisons
Corticosteroid
Corticosteroids
COVID-19
database
Effect
Effects
eight
events
Evidence
evidence of
Families
FIVE
Fixed-effect meta-analysis
futility
GRADE
high risk
Hydroxychloroquine
Immunoglobulin
indicate
indication
indications
individual patient data meta-analyses
individuals
information
intensive care
Intervention effects
intravenous
Intravenous immunoglobulin
lack
life
Lopinavir
Lopinavir-ritonavir
mechanical ventilation
meta-analyses
Meta-analysis
moderate
Network meta-analysis
no evidence of
non-serious adverse
non-serious adverse events
on mechanical ventilation
outcome
outcomes
participant
Participants
patient data
performed
Primary outcomes
PRISMA
Quality of life
random error
random errors
random-effects meta-analyses
randomized clinical trial
randomized clinical trials
rapidly spreading disease
reached
reduce
reduced
Remdesivir
renal replacement therapy
replacement therapy
required
Research
risk
risk of death
risk ratio
risks of bia
Ritonavir
searched
second
secondary
Secondary outcomes
sequential analysis
Serious Adverse Event
Serious Adverse Events
single trial
standard care
statistically significant
systematic review
threshold
Tocilizumab
Treatment
treatment for COVID-19
treatment intervention
treatments of COVID-19
Trial
Trial methodology
trial sequential analyses
trial sequential analysis
website
with COVID-19
[DOI] 10.1371/journal.pone.0248132 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1371/journal.pone.0248132 PMC 바로가기 [Article Type] Meta-Analysis
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial
입원한 COVID-19의 응고병증: COVID-19 유행병에 대한 신속한 대응으로서 치료용 항응고제 대 표준 치료의 실용적인 무작위 통제 시험(RAPID COVID COAG – RAPID 실험): 무작위 통제 실험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
absence
acutely ill hospitalized medical patients
Admission
age
allergy
allocation concealment
allocation sequence
Alpha
America
and protocol
Anticoagulant
anticoagulation
antiplatelet
antithrombotic therapy
apixaban
arterial
bleeding
bleeding risk
Blinding
block sizes
blood cell
Brazil
can not
Canada
Care
Chain Reaction
changed
choice
clinical trial
clinically
clinician
Coagulation
Coagulopathy
Committee
complex
Composite
computer-generated
contraindication
control group
Controlled
COVID
COVID-19
Critical
Critical illness
cryoprecipitate
D-dimer
D-dimer value
Dabigatran
dalteparin
Date
death
defined
dependent on
detect
determine
diagnosis of SARS-CoV-2
diagnostic
Diagnostic imaging
discretion
disorder
dissemination
dose
dual
edoxaban
electrocardiogram
element
elevated
emergency room
enoxaparin
Enrollment
evaluated
exclusion criteria
expected
experimental group
fibrinogen
fondaparinux
frozen plasma
Health Organization
hemoglobin
heparin
heparin-induced thrombocytopenia
High dose
high risk
hospital
Hospital admission
hospitalised
Hospitalized
hospitalized patient
hospitalized patients
ICU
ICU admission
include
inclusion criteria
indicated
individual
inflammatory biomarkers
Informed consent
INR
intensive care
intensive care unit
Interactive Web Response System
intermediate dose
Invasive mechanical ventilation
involved
Ireland
isothermal amplification
judgement
limit
LMWH
Local
low molecular weight
low molecular weight heparin
Major
major bleeding
mechanical ventilation
Non-invasive
non-invasive positive pressure ventilation
nucleic acid
number
objective
occur
Open-label
open-label trial
outcome
oxygen
oxygen saturation
participant
Patient
patients
Phase 3
plasma
Platelet
Platelet count
Platelets
polymerase chain
polymerase chain reaction
positive pressure
positive pressure ventilation
power
Pregnancy
pressure ventilation
protocol
random
random allocation
randomised
randomised controlled trial
randomization
Randomized controlled trial
Rapid
recruited
red blood cell
renal replacement therapy
replacement therapy
response
responsible
reverse transcriptase
Reverse transcriptase polymerase chain reaction
risk
risk difference
rivaroxaban
room air
Sample size
Saudi Arabia
secondary
Secondary outcomes
Standard
standard care
status
stratified
study population
Study protocol
supplementary material
symptomatic
the patient
the United State
therapeutic anticoagulation
therapeutic dose
therapy
thrombocytopenia
Thromboembolism
Thromboprophylaxis
tinzaparin
transcriptase
transfusion
treated
Trial
Trial registration
two-sided
ULN
unfractionated heparin
United Arab Emirates
United States
Venous Thromboembolism
Ventilator-free days
Version
Warfarin
website
World Health Organization
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India
Tocilizumab, 지속적인 저산소증이 있는 중증 COVID-19 폐렴의 생존율 향상: 인도 뭄바이에서 추적 관찰한 후향적 코호트 연구
Observational Study
[키워드] 95% CI
addition
analysed
Analysis
Care
China
CO-RADS
control group
Controlled trial
controlled trials
controls
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 admission
COVID-19 cytokine storm
COVID-19 patient
COVID-19 pneumonia
Cox regression analysis
CT-severity score
cytokine
Cytokine storm
death
defined
FiO2
Follow-up
high mortality
hospital
hyperinflammatory state
Hyperinflammatory syndrome
hypoxia
IBM
IL-6
IL-6 receptor
IMPROVE
independent predictor
independent predictors
India
Interlukin-6
intravenously
less
log rank
median
minute
monoclonal antibody
Mortality
multivariate
multivariate Cox regression
multivariate Cox regression analysis
Mumbai
non-rebreathing mask
observational study
oxygen
oxygen saturation
paO2/fiO2
PaO2/FiO2 ratio
Patient
predictor
reported
Result
retrospective
retrospective cohort study
saturation
severe coronavirus disease
Severe COVID-19 pneumonia
significantly
SPSS
standard care
statistical analysis
supplemental oxygen
survival
therapy
Tocilizumab
Treatment
triggered
was performed
[DOI] 10.1186/s12879-021-05912-3 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1186/s12879-021-05912-3 PMC 바로가기 [Article Type] Observational Study
Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
Lopinavir/ritonavir: COVID-19 치료에서 HIV 감염에 대한 오래된 약물 용도 변경
Review
[키워드] 3CL pro
Antiviral treatment
approved
benefit
cause
chymotrypsin
COVID-19
COVID-19 pandemic
COVID-19 treatment
drug
early phase
effective
Efficacy
Efficacy and safety
emergency treatment
Genetic
HIV infection
Infection
inhibit
Lopinavir
Lopinavir/ritonavir
LPV
MERS-CoV
protease
Protease inhibitor
repurposing
Ritonavir
SARS-CoV
SARS-CoV-2
SARS-COV-2 infection
similarity
standard care
tested
the disease
treat
Treatment
Viral
viral infection
viral infections
virus
viruses
[DOI] 10.1016/j.bj.2020.11.005 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.bj.2020.11.005 PMC 바로가기 [Article Type] Review
Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
IFNβ1과 로피나비르-리토나비르의 병용 요법은 중증 COVID-19 감염 환자의 산소 공급, 생존 및 퇴원을 증가시킵니다.
Article
[키워드] age
all-cause mortality
Analysis
antiviral effects
caused
clinical study
Combination
Comorbidity
conducted
control group
coronavirus
COVID-19
COVID-19 patient
COVID-19 patients
COVID-19 treatment
death rate
defined
determine
dose
during treatment
Efficacy
hospital
hospitalized patient
IFN-β1-a
immunomodulatory
in vitro activity
in vivo
increase
infection with SARS-CoV-2
inflammatory cells
inhibit
Inpatient
intensive care
interferon
interferon beta
Interferon beta-1a
International
Lopinavir
Lopinavir-ritonavir
Lopinavir/ritonavir
mediator
Mortality
Multivariate analysis
Noninvasive ventilation
outcome
Oxygenation
patients died
receiving
remained
required
Retrospective study
risk of death
Ritonavir
SARS-CoV-2
Sex
shown
significantly
standard care
survival
the disease
therapy
Treatment
virus
was done
[DOI] 10.1016/j.intimp.2020.107329 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.intimp.2020.107329 PMC 바로가기 [Article Type] Article